ALNY logo

Alnylam Pharmaceuticals, Inc. (ALNY) EBIT

Annual EBIT:

-$235.52M+$76.78M(+24.59%)
December 31, 2024

Summary

  • As of today, ALNY annual earnings before interest & taxes is -$235.52 million, with the most recent change of +$76.78 million (+24.59%) on December 31, 2024.
  • During the last 3 years, ALNY annual EBIT has risen by +$473.61 million (+66.79%).
  • ALNY annual EBIT is now -5478.33% below its all-time high of -$4.22 million, reached on December 31, 2002.

Performance

ALNY EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYincome statement metrics

Quarterly EBIT:

$4.89M+$7.84M(+265.69%)
June 30, 2025

Summary

  • As of today, ALNY quarterly earnings before interest & taxes is $4.89 million, with the most recent change of +$7.84 million (+265.69%) on June 30, 2025.
  • Over the past year, ALNY quarterly EBIT has dropped by -$17.20 million (-77.87%).
  • ALNY quarterly EBIT is now -97.31% below its all-time high of $181.63 million, reached on September 30, 2023.

Performance

ALNY Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYincome statement metrics

TTM EBIT:

-$227.34M-$17.20M(-8.19%)
June 30, 2025

Summary

  • As of today, ALNY TTM earnings before interest & taxes is -$227.34 million, with the most recent change of -$17.20 million (-8.19%) on June 30, 2025.
  • Over the past year, ALNY TTM EBIT has dropped by -$296.38 million (-429.27%).
  • ALNY TTM EBIT is now -429.27% below its all-time high of $69.04 million, reached on June 30, 2024.

Performance

ALNY TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherALNYincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

ALNY EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+24.6%-77.9%-429.3%
3Y3 Years+66.8%+102.1%+72.2%
5Y5 Years+73.4%+103.2%+72.7%

ALNY EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+75.8%-97.3%+101.3%-429.3%+77.7%
5Y5-Yearat high+75.8%-97.3%+101.3%-429.3%+77.7%
All-TimeAll-Time-5478.3%+75.8%-97.3%+101.3%-429.3%+77.7%

ALNY EBIT History

DateAnnualQuarterlyTTM
Jun 2025
-
$4.89M(+265.7%)
-$227.34M(-8.2%)
Mar 2025
-
-$2.95M(+98.1%)
-$210.13M(+10.8%)
Dec 2024
-$235.52M(+24.6%)
-$154.99M(-108.6%)
-$235.52M(-26.0%)
Sep 2024
-
-$74.29M(-436.3%)
-$186.88M(-370.7%)
Jun 2024
-
$22.09M(+178.0%)
$69.04M(+135.0%)
Mar 2024
-
-$28.33M(+73.4%)
-$197.22M(+36.8%)
Dec 2023
-$312.30M(+67.8%)
-$106.35M(-158.6%)
-$312.30M(+18.5%)
Sep 2023
-
$181.63M(+174.4%)
-$383.06M(+58.8%)
Jun 2023
-
-$244.17M(-70.3%)
-$929.55M(-1.3%)
Mar 2023
-
-$143.41M(+19.0%)
-$917.44M(+5.5%)
Dec 2022
-$971.02M(-36.9%)
-$177.11M(+51.5%)
-$971.02M(+4.6%)
Sep 2022
-
-$364.86M(-57.2%)
-$1.02B(-24.6%)
Jun 2022
-
-$232.06M(-17.8%)
-$816.51M(-10.4%)
Mar 2022
-
-$196.99M(+11.9%)
-$739.36M(-4.3%)
Dec 2021
-$709.12M(+8.0%)
-$223.49M(-36.3%)
-$709.12M(-1.2%)
Sep 2021
-
-$163.96M(-5.8%)
-$700.72M(+7.9%)
Jun 2021
-
-$154.91M(+7.1%)
-$760.48M(-0.6%)
Mar 2021
-
-$166.76M(+22.5%)
-$756.22M(+1.9%)
Dec 2020
-$771.10M(+12.9%)
-$215.08M(+3.9%)
-$771.10M(+7.4%)
Sep 2020
-
-$223.72M(-48.5%)
-$832.61M(-1.8%)
Jun 2020
-
-$150.66M(+17.1%)
-$817.81M(+7.7%)
Mar 2020
-
-$181.65M(+34.3%)
-$885.68M(+0.8%)
Dec 2019
-$885.25M(-16.4%)
-$276.58M(-32.4%)
-$892.82M(-14.1%)
Sep 2019
-
-$208.93M(+4.4%)
-$782.60M(+5.5%)
Jun 2019
-
-$218.52M(-15.7%)
-$828.22M(-3.3%)
Mar 2019
-
-$188.79M(-13.5%)
-$802.06M(-5.4%)
Dec 2018
-$760.67M(-52.1%)
-$166.36M(+34.6%)
-$760.67M(-2.6%)
Sep 2018
-
-$254.56M(-32.3%)
-$741.62M(-21.0%)
Jun 2018
-
-$192.35M(-30.5%)
-$612.86M(-13.3%)
Mar 2018
-
-$147.41M(-0.1%)
-$540.98M(-8.2%)
Dec 2017
-$500.09M(-17.8%)
-$147.30M(-17.1%)
-$500.09M(-6.8%)
Sep 2017
-
-$125.80M(-4.4%)
-$468.22M(-4.3%)
Jun 2017
-
-$120.47M(-13.1%)
-$449.09M(-6.7%)
Mar 2017
-
-$106.51M(+7.7%)
-$421.07M(+0.8%)
Dec 2016
-$424.59M(-43.4%)
-$115.43M(-8.2%)
-$424.59M(-5.7%)
Sep 2016
-
-$106.68M(-15.4%)
-$401.67M(-7.6%)
Jun 2016
-
-$92.45M(+16.0%)
-$373.32M(-5.5%)
Mar 2016
-
-$110.03M(-18.9%)
-$353.81M(-19.5%)
Dec 2015
-$296.01M(-60.7%)
-$92.51M(-18.1%)
-$296.01M(-18.8%)
Sep 2015
-
-$78.33M(-7.4%)
-$249.21M(-15.3%)
Jun 2015
-
-$72.94M(-39.7%)
-$216.08M(-12.5%)
Mar 2015
-
-$52.22M(-14.2%)
-$192.03M(-4.2%)
Dec 2014
-$184.21M
-$45.71M(-1.1%)
-$184.21M(-9.6%)
Sep 2014
-
-$45.20M(+7.6%)
-$168.09M(-8.4%)
Jun 2014
-
-$48.90M(-10.1%)
-$155.13M(-21.6%)
DateAnnualQuarterlyTTM
Mar 2014
-
-$44.41M(-50.1%)
-$127.55M(-37.2%)
Dec 2013
-$92.94M(-46.2%)
-$29.59M(+8.2%)
-$92.94M(-7.2%)
Sep 2013
-
-$32.23M(-51.2%)
-$86.70M(-19.4%)
Jun 2013
-
-$21.31M(-117.4%)
-$72.62M(-14.6%)
Mar 2013
-
-$9.80M(+58.0%)
-$63.37M(+0.3%)
Dec 2012
-$63.57M(-16.0%)
-$23.35M(-28.7%)
-$63.57M(-18.2%)
Sep 2012
-
-$18.15M(-50.4%)
-$53.80M(-11.9%)
Jun 2012
-
-$12.07M(-20.7%)
-$48.09M(+2.1%)
Mar 2012
-
-$10.00M(+26.4%)
-$49.14M(+10.4%)
Dec 2011
-$54.82M(-25.3%)
-$13.59M(-9.2%)
-$54.82M(-2.8%)
Sep 2011
-
-$12.44M(+5.2%)
-$53.31M(-7.5%)
Jun 2011
-
-$13.12M(+16.3%)
-$49.60M(-3.1%)
Mar 2011
-
-$15.68M(-29.8%)
-$48.11M(-10.0%)
Dec 2010
-$43.74M(+7.0%)
-$12.08M(-38.4%)
-$43.74M(-13.2%)
Sep 2010
-
-$8.73M(+24.9%)
-$38.63M(+2.3%)
Jun 2010
-
-$11.63M(-2.8%)
-$39.55M(+21.4%)
Mar 2010
-
-$11.31M(-62.3%)
-$50.33M(-7.1%)
Dec 2009
-$47.01M(-90.6%)
-$6.97M(+27.8%)
-$47.01M(-5.2%)
Sep 2009
-
-$9.65M(+56.9%)
-$44.68M(-16.8%)
Jun 2009
-
-$22.41M(-180.9%)
-$38.26M(-33.4%)
Mar 2009
-
-$7.98M(-72.1%)
-$28.68M(-16.3%)
Dec 2008
-$24.66M(+68.8%)
-$4.64M(-43.4%)
-$24.66M(-177.8%)
Sep 2008
-
-$3.23M(+74.8%)
-$8.88M(+84.4%)
Jun 2008
-
-$12.83M(-224.3%)
-$56.98M(+3.6%)
Mar 2008
-
-$3.96M(-135.5%)
-$59.10M(+25.3%)
Dec 2007
-$79.14M(-100.3%)
$11.15M(+121.7%)
-$79.14M(+21.1%)
Sep 2007
-
-$51.34M(-243.3%)
-$100.28M(-74.3%)
Jun 2007
-
-$14.95M(+37.7%)
-$57.54M(-7.2%)
Mar 2007
-
-$23.99M(-140.2%)
-$53.70M(-35.9%)
Dec 2006
-$39.50M(+9.1%)
-$9.99M(-16.1%)
-$39.50M(+11.1%)
Sep 2006
-
-$8.60M(+22.5%)
-$44.43M(+4.4%)
Jun 2006
-
-$11.11M(-13.4%)
-$46.49M(+0.2%)
Mar 2006
-
-$9.80M(+34.3%)
-$46.59M(-7.2%)
Dec 2005
-$43.47M(-34.7%)
-$14.92M(-39.8%)
-$43.47M(-27.5%)
Sep 2005
-
-$10.67M(+4.8%)
-$34.09M(-14.2%)
Jun 2005
-
-$11.20M(-67.7%)
-$29.84M(-16.5%)
Mar 2005
-
-$6.68M(-20.8%)
-$25.61M(+20.6%)
Dec 2004
-$32.26M(-57.8%)
-$5.53M(+13.9%)
-$32.26M(+31.8%)
Sep 2004
-
-$6.43M(+7.9%)
-$47.31M(-15.8%)
Jun 2004
-
-$6.97M(+47.7%)
-$40.84M(-14.6%)
Mar 2004
-
-$13.33M(+35.2%)
-$35.65M(-51.2%)
Dec 2003
-$20.45M(-384.3%)
-$20.58M(>-9900.0%)
-$23.59M(-684.6%)
Sep 2003
-
$44.00K(+102.5%)
-$3.01M(+1.4%)
Jun 2003
-
-$1.78M(-40.9%)
-$3.05M(-140.9%)
Mar 2003
-
-$1.27M
-$1.27M
Dec 2002
-$4.22M
-
-

FAQ

  • What is Alnylam Pharmaceuticals, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. annual EBIT year-on-year change?
  • What is Alnylam Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
  • What is Alnylam Pharmaceuticals, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Alnylam Pharmaceuticals, Inc.?
  • What is Alnylam Pharmaceuticals, Inc. TTM EBIT year-on-year change?

What is Alnylam Pharmaceuticals, Inc. annual earnings before interest & taxes?

The current annual EBIT of ALNY is -$235.52M

What is the all-time high annual EBIT for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$4.22M

What is Alnylam Pharmaceuticals, Inc. annual EBIT year-on-year change?

Over the past year, ALNY annual earnings before interest & taxes has changed by +$76.78M (+24.59%)

What is Alnylam Pharmaceuticals, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of ALNY is $4.89M

What is the all-time high quarterly EBIT for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is $181.63M

What is Alnylam Pharmaceuticals, Inc. quarterly EBIT year-on-year change?

Over the past year, ALNY quarterly earnings before interest & taxes has changed by -$17.20M (-77.87%)

What is Alnylam Pharmaceuticals, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of ALNY is -$227.34M

What is the all-time high TTM EBIT for Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is $69.04M

What is Alnylam Pharmaceuticals, Inc. TTM EBIT year-on-year change?

Over the past year, ALNY TTM earnings before interest & taxes has changed by -$296.38M (-429.27%)
On this page